No Statins Before Heart Surgery, Study Suggests

WEDNESDAY, May 4, 2016 -- Taking cholesterol-lowering statins right before heart surgery, once touted as a way to prevent common postoperative complications, has no benefit and may even cause harm, a new study suggests. In that setting, Crestor...
Source: Drugs.com - Daily MedNews - Category: Journals (General) Source Type: news

Related Links:

ConclusionsOur results suggest that metformin users are more likely to initiate preventive therapies and engage in other healthy behaviours. Failure to account for these behaviours may introduce healthy user bias into studies evaluating the effects of oral antihyperglycemic therapies.RésuméObjectifsLe biais lié aux utilisateurs sains selon lequel les patients ayant recours aux soins de santé sont plus susceptibles d'entreprendre des traitements préventifs et d'adopter des comportements sains liés au mode de vie est bien connu dans les études observationnelles, particuli&egra...
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
This Monday evening our next podcast becomes available. Dr. Gustavo Heudebert and I discuss another article about risk prediction. This topic has become a recurring theme on the Annals On Call podcast. Why is risk prediction so important? In 2019 we make many decisions about prevention and testing based on risk prediction. In addition we also estimate harms and benefits. All these predictive models have advantages and flaws. In making a decision for statin use (another upcoming episode), we have to estimate the risk of cardiovascular events, how much taking a statin will decrease that risk, and the probability and type...
Source: DB's Medical Rants - Category: Internal Medicine Authors: Tags: Medical Rants Source Type: blogs
Source: Clinical Trials And Noteworthy Treatments For Brain Tumors - Category: Cancer & Oncology Source Type: clinical trials
The cost of cardiac care, statin adherence and mortality, syncope, ultra-processed food, and heart failure survival are discussed in this week's podcast.theheart.org on Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Background: Cancer is the second leading cause of death worldwide next to cardiovascular diseases. Despite the advancement in screening, early diagnosis, and development in treatment technology in last several decades, cancer incidence overall, particularly that of gastrointestinal (GI) cancers, is far from being controlled, and is expected to increase worldwide.Summary: Although numerous preclinical and population-based clinical studies have already made important progress in restraining the overall cancer incidence and mortality, the full potential of preventive strategy is still far from being realized, and remains at a...
Source: Digestive Diseases - Category: Gastroenterology Source Type: research
Authors: Kumar S Abstract The prevalence of obesity-associated diabetes is increasing dramatically in the UK and worldwide. Obesity, particularly abdominal obesity, is not only associated with other cardiovascular risk factors, but is an independent cardiometabolic risk factor for diabetes and cardiovascular disease. Thus, the focus of obesity management, especially in patients with prediabetes and Type 2 diabetes, should encompass cardiometabolic risk reduction as well as weight loss. Lifestyle and diet modification should form the basis of all effective strategies for weight reduction. Pharmacotherapy provides an...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Authors: Duleba AJ, Pawelczyk L PMID: 30743799 [PubMed]
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Previous preclinical investigations based on the inhibition of the Rho/ROCK/CTGF pathway brought the biological rationale for this bicentric phase II clinical trial on the use of statins for the treatment of established radio-induced fibrosis. This trial showed that pravastatin (40mg/day for 12 months) is a safe and efficient anti-fibrotic agent in patients with established grade ≥2 cutaneous and subcutaneous fibrosis after head and neck cancer radiotherapy. These results support the concept of fibrosis reversibility.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
In this study, the GSH‐depletion treatment established an acute kidney injury mouse model due t o Mb release from the damaged skeletal muscle. This mouse model would be useful for predicting potential acute kidney injury risks in non‐clinical drug development.
Source: Journal of Applied Toxicology - Category: Toxicology Authors: Tags: RESEARCH ARTICLE Source Type: research
(Queen Mary University of London) High cholesterol has been found to be a possible risk factor for the development of motor neurone disease (MND), according to a large study of genetic data led in the UK by Queen Mary University of London, in collaboration with the National Institutes of Health in the USA.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Cardiology | Cholesterol | Crestor | General Medicine | Heart | Rosuvastatin | Statin Therapy | Study